{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:15:29Z","timestamp":1772558129665,"version":"3.50.1"},"reference-count":5,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2019,8,17]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate whether immunological response to influenza vaccination is impaired in patients who are receiving secukinumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Subjects suffering from psoriatic arthritis or ankylosing spondylitis who were receiving treatment with secukinumab and healthy volunteers were included.<\/jats:p>\n                  <jats:p>All participants received seasonal inactivated trivalent influenza vaccine recommended by the WHO in the 2017\u20132018 northern hemisphere influenza season, which contained an A\/Michigan\/45\/2015 (H1N1)pdm09-like virus, an A\/Hong Kong\/4801\/2014 (H3N2)-like virus and a B\/Brisbane\/60\/2008-like virus.<\/jats:p>\n                  <jats:p>Haemagglutination inhibition was used to evaluate basal antibody (Ab) titres against the three in\ufb02uenza vaccine virus strains just before vaccination and at least 4 weeks after the vaccine administration. Response to vaccine was considered as &gt;4-fold increases in Ab titre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty subjects, 17 patients and 13 healthy controls, with a follow-up duration of 33\u00b18 days, were analysed. There were no demographic differences between groups. Patients and controls achieved a median of 4.6-fold and 4.0-fold increases, respectively, for anti H1N1 and almost 4.0 (3.7) for patients and 5.3 for controls for anti-B Ab. Both groups presented a poor response against H3N2, with &lt;1.5-fold increase. Seroconversion rates were similar in both groups. Secukinumab did not influence the response to the influenza vaccine (relative risk: 1.09 (95% CI 0.58 to 2.07) for H1N1, RR: 1.53 (95% CI 0.15 to 15.0) for H3N2 and RR: 0.72 (95% CI 0.32 to 1.83) for B strain).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In our study, secukinumab has no effect on the immunogenic response to the influenza vaccine.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2019-001018","type":"journal-article","created":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T07:35:18Z","timestamp":1567582518000},"page":"e001018","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Secukinumab does not impair the immunogenic response to the influenza vaccine in patients"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-6814","authenticated-orcid":false,"given":"Patricia","family":"Richi","sequence":"first","affiliation":[{"name":"Rheumatology Department, Infanta Sof\u00eda University Hospital, San Sebastian de los Reyes, Spain"},{"name":"School of Medicine, European University of Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Bactereology Department, BR Salud Laboratories, San Sebastian de los Reyes, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"de Ory","sequence":"additional","affiliation":[{"name":"National Microbiology Centre, CIBER-ESP, Instituto de Salud Carlos III, Majadahonda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Guti\u00e9rrez-Larraya","sequence":"additional","affiliation":[{"name":"School of Medicine, European University of Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Casas","sequence":"additional","affiliation":[{"name":"National Microbiology Centre, Instituto de Salud Carlos III Campus de Majadahonda, Majadahonda, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Jim\u00e9nez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Infanta Sof\u00eda University Hospital, San Sebastian de los Reyes, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cava","sequence":"additional","affiliation":[{"name":"BR Salud Laboratories, San Sebastian de los Reyes, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fernandez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Infanta Sof\u00eda University Hospital, San Sebastian de los Reyes, Spain"},{"name":"School of Medicine, European University of Madrid, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"key":"2025090313311396000_5.2.e001018.1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025090313311396000_5.2.e001018.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137216"},{"key":"2025090313311396000_5.2.e001018.3","unstructured":"Centers for Disease Control and Prevention . Summary of the 2017-2018 influenza season. Available: https:\/\/www.cdc.gov\/flu\/about\/season\/flu-season-2017-2018.htm [Accessed Mar 2019]."},{"key":"2025090313311396000_5.2.e001018.4","first-page":"2917","article-title":"The effect of Secukinumab on the immunogenicity of influenza vaccine in patients with psoriatic arthritis (Abstract)","volume":"70","author":"Elkayam","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313311396000_5.2.e001018.5","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00386-12"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2019-001018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:31:25Z","timestamp":1756931485000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2019-001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":5,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,3]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/rmdopen-2019-001018"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2019-001018","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}